Takeda's orexin agonist Orzeyful has been approved in the US to treat narcolepsy type 1 (NT1) in adults, becoming the first ...

Stephanie Watel is a Contributing Writer at DualShockers who has been covering games professionally since 2022. She specializes in guides and reviews, with additional experience writing lists and ...

Tamil Nadu AAR classifies compostable PLA-PBAT bags under HSN 3923 and denies 5% GST as they lacked IS 17899:2022 ...

Q2 2026 Earnings Call August 10, 2026 4:30 PM EDTCompany ParticipantsChinmay Shukla - Senior Vice President of ...

A fresh start wants more courage and more heart. The New Moon in Leo arrives at 1:36 PM EDT, inviting us to reset how we ...

Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027Strategic operating plan ...

U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby - Attruby is the first ATTR-CM therapy associated with ...

Amgen Inc. ( AMGN) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDT My name is Julianne, and I will be your conference facilitator today for the Amgen Q2 Earnings Conference Call. I would now like to ...

Grades for A-levels and a number of vocational qualifications will be published on Thursday.

Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.

Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular ...